GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acorda Therapeutics Inc (FRA:CDG) » Definitions » Price-to-Free-Cash-Flow

Acorda Therapeutics (FRA:CDG) Price-to-Free-Cash-Flow : N/A (As of Jun. 08, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Acorda Therapeutics Price-to-Free-Cash-Flow?

As of today (2024-06-08), Acorda Therapeutics's share price is €8.423. Acorda Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €-20.03. Hence, Acorda Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Acorda Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 13 years, Acorda Therapeutics's highest Price-to-Free-Cash-Flow Ratio was 87.71. The lowest was 3.07. And the median was 24.65.

FRA:CDG's Price-to-Free-Cash-Flow is not ranked *
in the Drug Manufacturers industry.
Industry Median: 22.85
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Acorda Therapeutics's Free Cash Flow per Share for the three months ended in Mar. 2024 was €-14.95. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was €-20.03.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 58.60% per year.

During the past 13 years, Acorda Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 76.90% per year. The lowest was -9.00% per year. And the median was 54.70% per year.


Acorda Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Acorda Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acorda Therapeutics Price-to-Free-Cash-Flow Chart

Acorda Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Acorda Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Acorda Therapeutics's Price-to-Free-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Acorda Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acorda Therapeutics's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acorda Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Acorda Therapeutics's Price-to-Free-Cash-Flow falls into.



Acorda Therapeutics Price-to-Free-Cash-Flow Calculation

Acorda Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=8.423/-20.026
=N/A

Acorda Therapeutics's Share Price of today is €8.423.
Acorda Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-20.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Acorda Therapeutics  (FRA:CDG) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Acorda Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Acorda Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Acorda Therapeutics (FRA:CDG) Business Description

Traded in Other Exchanges
Address
2 Blue Hill Plaza, 3rd Floor, Pearl River, New York, NY, USA, 10965
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.

Acorda Therapeutics (FRA:CDG) Headlines

No Headlines